NCT02077452View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HMS5552

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Hua Medicine Limited

INDUSTRY

NCT02077452 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter